2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 1 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 222 | - | - | ||
| 383 | - | - | ||
| 111 | - | - | ||
| 44 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·12 t sittenDoctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·7 t sittenGo to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.
·5 t sittenIt would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?- ·1 päivä sittenToday's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1 päivä sitten · Muokattu1 päivä sitten · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%·26.5. · Muokattu@alle One must be realistic, something the company has also gradually given us the opportunity to see. Last summer the hype was big. It was an exciting time, but it was based on somewhat premature visions from some. I myself fell for it and hoped for a partnership back then. I myself believe, after dialogue with AI, that the PancreaSure partnership should happen between Sept - Nov 2026. (Gemini) AI argues for this based on the need for capital. The capital will run out around that time of year. Then the medicare application is on its way and perhaps that will be the optimal courtship Immunovia can make for value protection with a partner? Nothing is certain there. But I somewhat believe in AI's argumentation. Can it happen this summer, yes no one can know. I probably think that what Borcherdinger has shown us, that they don't sell themselves too early, makes it difficult with summer 2026. @Motorsav yes I am for an open and realistic dialogue. If you have good arguments to show that something is going the wrong way, it should be shared. But if it's just to rub salt in the wound, I am against negative criticism. You usually end up in that camp then. I welcome it from you when it is justified. Immunovia seems to be trying as hard and strongly as they can for success now. That is what my eyes see. You are allowed to disagree.
·22.5.Great that Avanza Pension continues to buy shares!·22.5. · MuokattuLet's hope they buy enough then to outsmart the robot that has created an absolutely artificial ceiling at 20 öre. This stock is absolutely not in a healthy free float, but is manipulated to trigger stop loss sales, so that some give up holding the stock in their custody account. Without me claiming what the stock might actually be worth. This will freshen up a bit beyond 2026. News is guaranteed to come. Most likely they will succeed with a partnership. And Finansinspektionen is mobile in such manipulation approximately like an old man with severely debilitating Alzheimer's. Despite that "the traffic light" about type of manipulation of "the tape" continues day in and day out
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenDoctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·7 t sittenGo to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·5 t sittenIt would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1 päivä sittenToday's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1 päivä sitten · Muokattu1 päivä sitten · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%·26.5. · Muokattu@alle One must be realistic, something the company has also gradually given us the opportunity to see. Last summer the hype was big. It was an exciting time, but it was based on somewhat premature visions from some. I myself fell for it and hoped for a partnership back then. I myself believe, after dialogue with AI, that the PancreaSure partnership should happen between Sept - Nov 2026. (Gemini) AI argues for this based on the need for capital. The capital will run out around that time of year. Then the medicare application is on its way and perhaps that will be the optimal courtship Immunovia can make for value protection with a partner? Nothing is certain there. But I somewhat believe in AI's argumentation. Can it happen this summer, yes no one can know. I probably think that what Borcherdinger has shown us, that they don't sell themselves too early, makes it difficult with summer 2026. @Motorsav yes I am for an open and realistic dialogue. If you have good arguments to show that something is going the wrong way, it should be shared. But if it's just to rub salt in the wound, I am against negative criticism. You usually end up in that camp then. I welcome it from you when it is justified. Immunovia seems to be trying as hard and strongly as they can for success now. That is what my eyes see. You are allowed to disagree.
- ·22.5.Great that Avanza Pension continues to buy shares!·22.5. · MuokattuLet's hope they buy enough then to outsmart the robot that has created an absolutely artificial ceiling at 20 öre. This stock is absolutely not in a healthy free float, but is manipulated to trigger stop loss sales, so that some give up holding the stock in their custody account. Without me claiming what the stock might actually be worth. This will freshen up a bit beyond 2026. News is guaranteed to come. Most likely they will succeed with a partnership. And Finansinspektionen is mobile in such manipulation approximately like an old man with severely debilitating Alzheimer's. Despite that "the traffic light" about type of manipulation of "the tape" continues day in and day out
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 222 | - | - | ||
| 383 | - | - | ||
| 111 | - | - | ||
| 44 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
27 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·12 t sittenDoctor on new cancer medicine: "First time we beat chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik·7 t sittenGo to homepage. Logo, Ny Teknik Log in Search Search... INNOVATION Archive image. Fredrik Sandberg/TT Doctor on new cancer medicine: "First time we knock out chemotherapy" A new drug can make people suffering from pancreatic cancer survive twice as long, according to a new study. TT/Ny Teknik Published 1 Jun 2026 at 13.01 Last updated 2 Jun 2026 at 08.39 Advertisement In the study, on 500 patients in the USA with metastatic cancer, survival doubled from just over half a year to over 13 months compared to patients who instead received chemotherapy, reports Dagens Medicin. – "I am happy about this. The survival benefit is very large considering how difficult to treat this disease is," says Daniel Öhlund, oncologist and chief physician at Norrlands University Hospital in Umeå, to the newspaper. – "It is also the first time we get a drug that is more effective than cytostatics for broad patient groups." The drug, daraoxanrasib, inhibits a protein that is driving tumor development in most cases.·5 t sittenIt would have been a dream if they could also get something that helps them out of the death sentence. Maybe it "buys them a little time so they can manage to make some new bold moves"?
- ·1 päivä sittenToday's trading. Remember that we have to go all the way back to October 2025 to reach the previous issue. Those who have had cold feet should have disappeared (sold out at a loss) a long time ago. At 09:08 one sees a gap between sellers' price level in øre 19.92 and 20 and 20.05 up to 20.8. They have been doing this for months to trigger stop-loss. As soon as someone buys slightly larger blocks again, they withdraw and then re-evaluate the next level. This is robot trading (manipulation). One day when news is released, they will not be able to defend these heavy bluff sales of theirs. I believe in a GAP-up one day in the future. Of course impossible to predict exactly when. That is what I believe about the trading in this stock.
- 1 päivä sitten · Muokattu1 päivä sitten · MuokattuJeg mener vi har nådd den februar-spåing som Borcherdinger gjorde om NY-godkjennelse veldig nært på. Så kan han jo ha spådd bittelitt feil. Men vi burde jo omtrentlig snart være i mål da? Får vi nådd nok en milepæle snart da? :) En eller annen dag vil jo New York-godkjenningen vel komme nokså sannsynlig. Og vi får en mellom-aktig boost i aksjekursen? Kan godkjenningen være priset inn allerede i dagens lave kurs? Jeg tviler litt. Det er vel vakuumet mellom neste nyhet vi føler på nå antar ihvertfall jeg. Finansiering er jo heller ikke endelig løst. Det vil vel være en betydelig aksjekursendring når finansiering som jo er et helt annet spørsmål, er løst på et eller annet vis. Så kommer det jo an på hvordan finansieringen blir løst.. Jeg spurte Gemini AI om hva som er hemskoen med New York godkjennelse for salg av PancreaSure i staten: "In the world of diagnostics, New York State approval is almost never a mere formality. While the final outcome will likely be positive, the process itself requires a meticulous "back-and-forth" where companies must actively feed the state specific pieces of data. Even though Immunovia cleared California’s strict Clinical Laboratory Evaluation Program (CLEP) guidelines and is approved in 49 states, New York’s Department of Health (NYSDOH) treats itself as a completely independent supreme regulatory body. They do not rubber-stamp any test based on another state's approval. The process involves specific data requirements and steps that explain why it takes time, along with the distinct pieces of information Immunovia must provide to satisfy New York. What New York Demands (The "Missing Pieces") When a company like Immunovia is "actively pursuing" New York approval, they are usually navigating a highly structured technical audit. The state requires a specialized, standalone application dossier that focuses heavily on three areas: Raw Validation Data: New York rarely accepts summarized clinical trial papers alone. Their reviewers typically demand the raw validation data from the clinical trials (such as the CLARITI study for PancreaSure). They want to re-verify how the test handles the 5-plex serum biomarkers (TIMP1, ICAM1, CTSD, TSP1, and CA 19-9) to ensure consistency. Standard Operating Procedures (SOPs) & QA: The NYSDOH evaluates the physical and digital workflow of the laboratory running the test. They require detailed documentation on how samples are shipped from New York clinics, how they are handled, and the exact software algorithms used to interpret the "positive" or "negative" cutoffs. The "Gating" Iteration: The approval process operates like a formal audit. New York reviews the submission, issues a list of highly technical questions or requests for clarification, and the company must submit amended protocols or extra data points. This cyclical nature is why it is rarely a quick administrative sign-off. Why Investors Can Rest Easy About the Outcome While it isn't a hands-off formality, it is highly likely a winnable process for Immunovia rather than a major roadblock. The California Indicator: California and New York have remarkably similar scientific standards for laboratory-developed tests (LDTs). Because Immunovia successfully cleared California’s rigorous hurdle, it proves that PancreaSure's clinical accuracy ($78.5\%$ sensitivity and $93.5\%$ specificity) and laboratory quality control are robust enough to withstand top-tier regulatory scrutiny. The company already has prestigious institutions inside New York, like NYU Langone/Perlmutter Cancer Center, implementing the test for patients via out-of-state framework arrangements. These centers understand the logistical gaps of traditional surveillance (like MRIs or endoscopic ultrasounds) and want local access. The Bottom Line It is a procedural hurdle, not a scientific doubt. Immunovia doesn't need to go back to the drawing board to invent new data or run new trials; they simply need to satisfy New York's administrative requirements by feeding them the exact quality-control documentation and raw data formatting they demand.
- ·22.5.When will the parties succeed in coming to an agreement, with a partnership for PancreaSure?3 ääntä PäättynytLiity Nordnet Socialiin nähdäksesi tuloksetsummer 202633%Sept - Nov 2026 sometime0%2027 sometime33%later33%·26.5. · Muokattu@alle One must be realistic, something the company has also gradually given us the opportunity to see. Last summer the hype was big. It was an exciting time, but it was based on somewhat premature visions from some. I myself fell for it and hoped for a partnership back then. I myself believe, after dialogue with AI, that the PancreaSure partnership should happen between Sept - Nov 2026. (Gemini) AI argues for this based on the need for capital. The capital will run out around that time of year. Then the medicare application is on its way and perhaps that will be the optimal courtship Immunovia can make for value protection with a partner? Nothing is certain there. But I somewhat believe in AI's argumentation. Can it happen this summer, yes no one can know. I probably think that what Borcherdinger has shown us, that they don't sell themselves too early, makes it difficult with summer 2026. @Motorsav yes I am for an open and realistic dialogue. If you have good arguments to show that something is going the wrong way, it should be shared. But if it's just to rub salt in the wound, I am against negative criticism. You usually end up in that camp then. I welcome it from you when it is justified. Immunovia seems to be trying as hard and strongly as they can for success now. That is what my eyes see. You are allowed to disagree.
- ·22.5.Great that Avanza Pension continues to buy shares!·22.5. · MuokattuLet's hope they buy enough then to outsmart the robot that has created an absolutely artificial ceiling at 20 öre. This stock is absolutely not in a healthy free float, but is manipulated to trigger stop loss sales, so that some give up holding the stock in their custody account. Without me claiming what the stock might actually be worth. This will freshen up a bit beyond 2026. News is guaranteed to come. Most likely they will succeed with a partnership. And Finansinspektionen is mobile in such manipulation approximately like an old man with severely debilitating Alzheimer's. Despite that "the traffic light" about type of manipulation of "the tape" continues day in and day out
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 119 | - | - | ||
| 222 | - | - | ||
| 383 | - | - | ||
| 111 | - | - | ||
| 44 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt